Loxo, Illumina to partner for diagnostic tool targeting cancer

(Reuters) – Drug developer Loxo Oncology said on Tuesday it is partnering with genetic testing company Illumina Inc on a diagnostic tool that will work with Loxo’s larotrectinib and another one of its experimental cancer drugs, across tumor types.

Source: Reuters Medical News

Leave a Reply

Your email address will not be published. Required fields are marked *